Trials / Recruiting
RecruitingNCT06477419
A Study of Sacituzumab Govitecan in People With Mesothelioma
Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Previously Treated Mesothelioma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacituzumab govitecan-hziy | After enrollment, participants will receive SG until disease progression or intolerable toxicity. |
Timeline
- Start date
- 2024-06-21
- Primary completion
- 2029-06-21
- Completion
- 2029-06-21
- First posted
- 2024-06-27
- Last updated
- 2025-07-15
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06477419. Inclusion in this directory is not an endorsement.